22-45 Getting a Vaccination? What about a nasal spray?
02/02/23 • 26 min
Dr. Robert Coleman, the Co-Founder and CEO of Codagenix, shows us how to precisely engineer viruses to be effective vaccines, which can be delivered nasally – you heard that right – no needle.
Dr. Robert Coleman, the Co-Founder and CEO of Codagenix, shows us how to precisely engineer viruses to be effective vaccines, which can be delivered nasally – you heard that right – no needle.
Previous Episode
23-03 Dr. Rob Ross, CEO, Surface Oncology
Surface Oncology's strategy to improve on the first generation of immuno-oncology drugs. Their Phase 2 trials in lung cancer and liver cancer are underway and recruiting.
Next Episode
Getting Immune Systems to Recognize HER2+ tumors - Dr. Randy Schatzman, President & CEO, Bolt Biotherapeutics
Bolt Biotherapeutics’ Dr. Randy Schatzman talks about the role of myeloid cells in teaching our immune systems to recognize tumors in our own bodies and then eliminate them. Nearly two dozen forms of HER2-related cancers are being studied. (16 mins)
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/biotech-nation-with-dr-moira-gunn-239455/22-45-getting-a-vaccination-what-about-a-nasal-spray-27869436"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to 22-45 getting a vaccination? what about a nasal spray? on goodpods" style="width: 225px" /> </a>
Copy